Takeda Pharmaceutical (NYSE:TAK) Issues FY 2026 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 3.009-3.009 for the period, compared to the consensus EPS estimate of 1.570. The company issued revenue guidance of $29.6 billion-$29.6 billion, compared to the consensus revenue estimate of $29.0 billion.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $17.77 on Thursday. The stock’s 50-day moving average is $16.23 and its two-hundred day moving average is $17.07. The firm has a market cap of $56.95 billion, a price-to-earnings ratio of 45.58 and a beta of -0.07. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.60 and a current ratio of 1.09.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, July 30th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.30. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%.The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.11 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Analysts predict that Takeda Pharmaceutical will post 1.12 earnings per share for the current year.

Analysts Set New Price Targets

TAK has been the topic of a number of recent research reports. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Finally, Weiss Ratings cut Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Takeda Pharmaceutical

Institutional investors have recently made changes to their positions in the stock. Parkside Financial Bank & Trust grew its stake in shares of Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after purchasing an additional 2,328 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Takeda Pharmaceutical in the third quarter valued at about $74,000. Finally, Kestra Advisory Services LLC purchased a new stake in Takeda Pharmaceutical during the fourth quarter worth about $101,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.